Overview

Generic Name(s):
volasertib
NCI Definition [1]:
A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.

Volasertib has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating volasertib, 2 are phase 1 (0 open).

CBFB-MYH11 Fusion, RUNX1-RUNX1T1 Fusion, and inv(16)(p13q22) are the most frequent biomarker inclusion criteria for volasertib clinical trials.

Acute myeloid leukemia is the most common disease being investigated in volasertib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Volasertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating volasertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bi 6727, polo-like kinase 1 inhibitor bi 6727, benzamide, n-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-, plk-1 inhibitor bi 6727, bi-6727, volasertib, polo-like kinase 1 inhibitor bi 6727
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
PLK1
NCIT ID [1]:
C79844

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.